Abstract
Liposomes are bilayer vesicles composed of phospholipids, which can contain the non-lipophilic drugs to increase its bioavailability and to enter the posterior segment of the eye. These liposomes can be formulated in different sizes via these four basic steps: drying lipids from the organic solvent, dispersing the lipid within an aqueous media, purification, and analyzing the product. Majority of the liposome formulations are generally composed of poly(ethylene glycol) (PEG)-modified lipids, which have been proven to increase circulation time. This drug delivery method renders both active and passive mechanism, which are specific to the targeted area. Liposomes act as barriers when they come in contact with ocular surfaces and protect therapeutic agents from the metabolic enzymes found at the tear junction. However, there are some challenges that still have to be tackled, for instance, sterilization, short shelf life, and also other unknown consequences of their long-term in vivo use. Even with the above issues, liposomes offer a sustained drug release, which reduces the frequency of the intravitreal injections and thus their side effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Halasz K, Kelly S, Sutariya V. Hypoxia inducible Factor-1 (HIF-1) as a target for ocular drug delivery. J Biomol Res Ther. 2017;6(1):e154.
Delamo E, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3–4):135–43. https://doi.org/10.1016/j.drudis.2007.11.002.
Sahoo S, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51. https://doi.org/10.1016/j.drudis.2007.10.021.
Hirani A, Grover A, Lee YW, Pathak Y, Sutariya V. Polymer-based therapies for posterior segment ocular disease. J Biomol Res Ther. 2014;03(01):e122. https://doi.org/10.4172/2167-7956.1000e122.
Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735–54. https://doi.org/10.1007/s13346-016-0339-2.
Pathak Y, Sutariya VB, Hirani AA. Nano-biomaterials for ophthalmic drug delivery. Springer, International Publishing Switzerland, 2016.
Deamer DW. From “Banghasomes” to liposomes: a memoir of Alec Bangham, 1921-2010. FASEB J. 2010;24(5):1308–10. https://doi.org/10.1096/fj.10-0503.
Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv. 2011;2011:1–14. https://doi.org/10.1155/2011/863734.
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. https://doi.org/10.3389/fphar.2015.00286.
Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol Liposomes. 2005;391:71–97. https://doi.org/10.1016/s0076-6879(05)91004-5.
Akbarzadeh A, Razaei-Sababady R, Davaran S, Woo Joo S, Zarghami N, Hanifehpour Y, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.
Jain R, Shastri J. Study of ocular drug delivery system using drug-loaded liposomes. Int J Pharm Investig. 2011;1(1):35. https://doi.org/10.4103/2230-973x.76727.
Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592–9. https://doi.org/10.1016/j.tips.2009.08.004.
Smith SB, Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel J, Sirotnak FM. Expression and differential polarization of the reduced-folate Transporter-1 and the folate receptor α in mammalian retinal pigment epithelium. J Biol Chem. 2000;275(27):20676–84. https://doi.org/10.1074/jbc.m002328200.
Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379(1):131–8. https://doi.org/10.1016/j.ijpharm.2009.06.020.
Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009;136(3):247–53. https://doi.org/10.1016/j.jconrel.2009.02.020.
Schaeffer HA, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22(2):220–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Halasz, K., Pathak, Y.V. (2018). Liposomes for Retina and Posterior Segment Disease. In: Patel, J., Sutariya, V., Kanwar, J., Pathak, Y. (eds) Drug Delivery for the Retina and Posterior Segment Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95807-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-95807-1_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95806-4
Online ISBN: 978-3-319-95807-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)